INTERGRATED DIA.H DL 025 Total Liabilities
INTERGRATED DIA.H DL 025 total liabilities. Based on the latest financial reports, INTERGRATED DIA.H DL 025 (8I8) has total liabilities worth €3.22 Billion EUR (≈ $3.76 Billion USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are INTERGRATED DIA.H DL 025's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of INTERGRATED DIA.H DL 025 (2021–2025)
Total liabilities of INTERGRATED DIA.H DL 025 from 2021 to 2025. This chart illustrates how INTERGRATED DIA.H DL 025's total liabilities have evolved over time, based on quarterly financial data.
INTERGRATED DIA.H DL 025 Competitors by Total Liabilities
The table below lists competitors of INTERGRATED DIA.H DL 025 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zespol Elektrowni Patnow Adamow Konin SA
WAR:ZEP
|
Poland | zł1.76 Billion |
|
WAWEL SA
WAR:WWL
|
Poland | zł116.87 Million |
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
USA | $124.44 Million |
|
Clinuvel Pharmaceuticals Ltd
AU:CUV
|
Australia | AU$20.68 Million |
|
NEOBO FASTIGHETER
ST:NEOBO
|
Sweden | Skr7.48 Billion |
|
P.C.B Tec
TA:PCBT
|
Israel | ILA76.95 Million |
|
Velos Acquisition I Corp.
NASDAQ:VLOS
|
USA | $21.66 Million |
|
PharmaEngine
TWO:4162
|
Taiwan | NT$112.86 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down INTERGRATED DIA.H DL 025's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see INTERGRATED DIA.H DL 025 assets under control.
Liquidity & Leverage Metrics
INTERGRATED DIA.H DL 025 Total Liabilities Ratios Explained
INTERGRATED DIA.H DL 025 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INTERGRATED DIA.H DL 025's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INTERGRATED DIA.H DL 025 (2021–2025)
The table below shows the annual total liabilities of INTERGRATED DIA.H DL 025 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.46 Billion ≈ $5.22 Billion |
+23.01% |
| 2024-12-31 | €3.63 Billion ≈ $4.24 Billion |
+35.97% |
| 2023-12-31 | €2.67 Billion ≈ $3.12 Billion |
-6.31% |
| 2022-12-31 | €2.85 Billion ≈ $3.33 Billion |
-17.22% |
| 2021-12-31 | €3.44 Billion ≈ $4.02 Billion |
-- |
About INTERGRATED DIA.H DL 025
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more